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ABSTRACT. The nuclear membrane is one of the major cellular barriers in the delivery of plasmid 
DNA (pDNA). Cell division has a positive influence on the expression efficiency since at the end of 
mitosis, pDNA or pDNA containing complexes near the chromatin are probably included by a random 
process in the nuclei of the daughter cells. However, very little is known about the nuclear inclusion of 
nanoparticles during cell division. Using the Xenopus nuclear envelope reassembly (XNER) assay, we 
found that the nuclear enclosure of nanoparticles was dependent on size (with 100 nm and 200 nm 
particles being better included than the 500 nm ones) and charge (with positively charged particles 
being better included than negatively charged or poly-ethyleneglycolated (PEG-ylated) ones) of the 
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beads. Also, coupling chromatin-targeting peptides to the polystyrene beads or pDNA complexes 
improved their inclusion by 2- to 3-fold. Upon microinjection in living HeLa cells, however, 
nanoparticles were never observed in the nuclei of cells post-division but accumulated in a specific 
perinuclear region, which was identified as the lysosomal compartment. This indicates that 
nanoparticles can end up in the lysosomes even when they were not delivered through endocytosis. To 
elucidate if the chromatin binding peptides also have potential in living cells, this additional barrier first 
has to be tackled, since it prevents free particles to be present near the chromatin at the moment of cell 
division.  
KEYWORDS. cell division, nuclear enclosure, Xenopus laevis, HeLa cells, pDNA delivery, nuclear 
exclusion, exocytosis 
INTRODUCTION. Gene therapy shows potential in the treatment of a wide variety of genetic 
disorders. For gene therapy to be successful, the nucleic acids should reach their target, which is situated 
intracellularly. Naked nucleic acids are poorly taken up by cells. Therefore, they are administered by 
using viral or non-viral vectors. In general, viral vectors provide high transfection efficiencies but suffer 
from the limited amount and size of the genetic material they can carry. Also, they can induce severe 
immune responses. Non-viral vectors are advantageous over viral vectors in that they are less expensive, 
easier and safer to make and more suitable for long time storage. They can also deliver much larger 
pieces of DNA when compared to viral methods1. Non-viral vectors mostly enter the cells by 
endocytosis. Then, they have to escape from the endosomal compartment and release their therapeutic 
DNA in the cytoplasm of the cells. Furthermore, the therapeutic DNA should stay intact and reach its 
target, which is the nucleus in the case of plasmid DNA (pDNA). Plasmid DNA delivery and expression 
remain challenging despite many years of non-viral gene therapy research. Although non-viral systems 
have many advantages, their expression efficiency is very low when compared to viral systems. Factors 
which decrease expression efficiency include cytoplasmic sequestration (by interactions with DNA 
binding proteins and cytoskeletal elements)2, 3, enzymatic degradation4, decomplexation from carrier 
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molecules5 and most importantly, lack of transport across the nuclear membrane, which is one of the 
major cellular barriers6, 7. In non-dividing cells, the transfer through the nuclear pore complexes (NPCs) 
of intact nuclear envelopes is very inefficient. Many studies suggest that although it is not impossible, 
larger molecules such as pDNA do not readily cross NPCs2, 8-11. Several attempts at improving non-viral 
entry of pDNA into the nucleus have been published, in which nuclear localization signal (NLS)  
containing proteins or peptides were attached to the pDNA by electrostatic interactions12 or covalent 
binding13. Also, attachment to cellular DNA binding proteins including histones14 and high-mobility 
group (HMG) proteins15, as well as DNA containing the Simian Virus 40 (SV40) promoter and origin of 
replication16
Interestingly, several groups have observed that the expression efficiencies of cationic lipid-, polymer- 
and peptide-based transfection reagents were two- to several hundred-fold higher in dividing as 
compared to non-dividing cells
, have been investigated. These attempts at improving the transport of DNA to the nucleus 
have however met with limited success.  
9, 11, 17-24. Also, cell division had a positive influence on the nuclear 
inclusion of colloidal gold particles25
 
. This suggests that transfection close to M phase is perhaps 
facilitated by nuclear membrane breakdown, since the disassembly of the nuclear envelope during cell 
division most likely facilitates access to the nucleoplasm and chromatin. It is plausible that the naked 
pDNA or nanoparticles near the chromatin are included by chance in the nuclei of the daughter cells 
during mitosis, as is presented in figure 1.  
 
Figure 1. Principle of nuclear inclusion during cell division. (Black) nanoparticles, (green) nuclear 
membrane, (red) golgi-apparatus and (blue) chromatin. 
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Previous studies which focused on the fate of nanoparticles and the dependence of their characteristics 
in living cells, mostly delivered the nanoparticles through uptake by endocytosis. It was reported, for 
example, that the pathway of internalization depends on the size of the polystyrene nanoparticles26. 
Furthermore, the uptake mechanism, uptake rate, cytotoxicity and exocytosis of gold nanoparticles of 
different size and shape were investigated27, 28. Recently, Errington and colleagues studied the fate of 
nanoparticles during the cell cycle. The quantum dots were asymmetricly and non-random diluted over 
daughter cells which is probably related to a survival mechanism of the cell responding to stress29
 
. 
Although the nuclear inclusion appears a very simple concept to study, very little is known on the 
nuclear entry of nanoparticles during cell division. How and to what extent can nanoparticles access the 
nucleoplasm during cell division? Is nuclear inclusion random or do nanoparticles need to interact with 
chromatin to be enclosed? Do the nanoparticles remain in the nucleoplasm during subsequent cell 
cycles? Many of these questions remain unanswered, although they are highly relevant for non-viral 
gene delivery. We addressed these open questions by studying to which extent nanoparticles are 
enclosed in artificial Xenopus laevis nuclei and in daughter nuclei of dividing HeLa cells. The Xenopus 
nuclear assembly reaction (XNER assay) functions as a model system, in which the enclosure of 
nanoparticles in fully functional artificial nuclei can be studied in the most ideal situation, e.g. without 
the presence of additional extracellular and intracellular barriers. In case of the HeLa cells the 
nanoparticles were microinjected into the cytosol so as to avoid additional intracellular barriers such as 
cellular uptake and endosomal escape, and to prevent that particles would be trapped inside endosomes 
through endocytic uptake. We investigated whether the size and charge of the nanoparticles had an 
influence on the nuclear inclusion and if the enclosure could be enhanced by modification of the 
nanoparticles by using chromatin binding peptides since one might expect more efficient enclosure by 
binding to the chromatin during cell division. 
 
 
 5 
MATERIAL AND METHODS.  
Green fluorescent carboxylated polystyrene beads (Molecular Probes®) of different size (100, 200 
and 500 nm) were used. These beads have a negative ζ-potential and were modified with Pluronic F-127 
(Sigma-Aldrich®) and dimethylamine-ethylamine (DMAEA) to obtain respectively poly-
ethyleneglycolated (PEG-ylated)
Polystyrene beads 
30 and positively charged beads (see Table 1). The latter is the result of 
an amide formation between the carboxylate groups on the beads and the amine group of DMAEA. The 
carboxylate groups were activated with an excess of EDC at pH 5. DMAEA (at pH 5) was added and 
this was shaken overnight. Then, Microcon-YM-100 (Millipore®) were used to purify the positively 
charged beads. These series of beads are called ‘non-targeted beads’. Additionally, the carboxylated 100 
nm beads were modified via a NH2-PEG-maleimide linker with 3 gluthatione-S-transferase (GST)-
tagged peptides, namely Mel-28, mutated Mel-28 or HMGA2β (Fig. 2A). Briefly, 10 mg/ml NH2-PEG-
maleimide (creative PEGworks) was added to 500 µl 0.4 % solution of the carboxylated beads and 
incubated overnight at 4 °C. Then, the beads were purified by centrifugation over Microcon-YM-100 
columns and recollected after 2 washing steps by reversed centrifugation. The modified beads were 
incubated overnight with 50 µg of glutathion-GST-tagged proteins to allow binding to the maleimide 
side of the NH2-PEG-maleimide linker. The beads were again purified by centrifugation over Microcon-
YM-100 columns and recollected after 2 washing steps by reversed centrifugation. Further on, these 
beads are called ‘targeted beads’. Mel-28, mutated Mel-28 and HMGA2β were prepared as described 
elsewhere31
 
. Diameter and ζ-potential measurements of the non-targeted beads were done with a 
ZETASIZER NANO (Malvern Instruments). 
As pDNA nanoparticles we made use of  pDNA complexed to 7.5 kDa linear poly-ethylene-imine 
(PEI) (kindly provided to us by Olivia Merkel, Marburg University, Germany). For targeting and 
microinjection experiments, pDNA was labelled with Cy5 (fluorescent red) using the Label IT
pDNA/PEI polyplexes 
® CyTM5 
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labelling kit (Mirus Bio Corporation) and purified by purification columns as supplied by the 
manufacturer. Complexes were prepared by adding a PEI polymer solution to an equal volume of a 0.04 
µg/µl pDNA solution to obtain a nitrogen to phosphate ratio (N/P ratio) of 10, followed by vortexing the 
dispersion for 10 seconds and were allowed to equilibrate at room temperature for 30 minutes prior to 
use. To obtain targeted pDNA/PEI nanoparticles, complexes were prepared with PEI polymers which 
were modified with peptides of Mel-28, mutated Mel-28 or HMGA2β through a NHS-PEG-maleimide 
linker. Briefly, 1 mg/ml PEI polymer solution was incubated with 10 times excess of NHS-PEG-
maleimide (Pierce, Thermo Scientific) and purified by a ZebaTM
 
 Desalt spin column (Thermo scientific) 
after 4 hours of incubation at room temperature. Then, 220 µl of the partially modified PEI polymers 
were incubated overnight at 4 °C with 13.5 µg of glutathion-GST-tagged peptides to allow binding to 
the maleimide side of the NHS-PEG-maleimide linker so that chromatin targeted PEI polymers were 
obtained. In this concentration, almost all glutathion-GST-tagged peptides bound to the PEI polymers, 
which makes further purification unnecessary. To be sure, however, the PEI complexes were 
additionally purified by centrifugation over Microcon-YM-100 columns and recollected after 2 washing 
steps by reversed centrifugation before use. The diameter and ζ-potential of the non-targeted and 
targeted pDNA/PEI polyplexes were measured with a ZETASIZER NANO (Malvern Instruments). 
The initial chromatin binding properties of Mel-28, mutated Mel-28 and HMGA2β were evaluated 
with immunostaining against the GST-fragment of the AT-hooks. Membrane-free extract was 
supplemented with GST alone or GST-AT-hooks at 1 µM final concentration, and incubated with 
chromatin for 10 minutes. Then, the chromatin was fixed with 4 % PFA in PBS for 10 minutes. The 
fixed chromatin was placed on top of 0.8 ml 30 % sucrose cushion in PBS and centrifuged onto poly-L-
lysine coated cover slips. Blocking was carried out for 30 minutes in 1 % BSA-PBS. Then, the samples 
were incubated with the primary anti-GST antibody in 1 % BSA-PBS for 2 hours, followed by extensive 
washing before the fluorescein-labelled secondary antibody (in 1 % BSA-PBS) was added for 1 hour. 
Immunostaining of GST-AT-hooks 
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After washing, the chromatin was stained by adding 0.1 µg/ml DAPI and the samples were visualized 
with a fluorescence microscope. 
 
Cytosolic extract and membrane fraction needed for the XNER assay were isolated from Xenopus 
laevis eggs and sperm chromatin was prepared from Xenopus leavis sperm (Xenopus laevis testis were 
also kindly provided by Kris Vleminckx Lab, VIB, Ghent) as previously described by Hetzer et al. 
(2000)
Xenopus nuclear envelope reassembly (XNER) assay 
32. To study the nuclear inclusion in the XNER assay, 1 µl of polystyrene beads (green)  or Cy5-
pDNA/PEI nanoparticles (red) were added to a mixture of sperm chromatin (0.6 µl) and cytosolic 
extract (20 µl) and incubated in a water bath at 20 °C for 20 minutes. Then, 1 µl membrane fraction, 1 
µl energy mix (127.5 mg/ml creatin phosphate, 2.5 mg/ml creatin kinase, 25 mM ATP and 25 mM GTP) 
and 1 µl glycogen (200 mg/ml) were added and this mixture was incubated in a water bath at 20 °C to 
allow the formation of artificial nuclei as described by Hetzer et al. (2000)32. After 90 minutes the 
artificial nuclei were stained with DiIC18 
 
(membrane staining) and DAPI (chromatin staining) and the 
enclosure of the nanoparticles in the nuclei was visualised with a Nikon EZC1-si (Nikon Belux, 
Brussels, Belgium) by fluorescence confocal laser scanning microscopy (CLSM) or epifluorescence 
microscopy. The particles were counted by moving up and down the Z-focus to visualize the artificial 
nuclei in 3-D. It should be noted that in the case of 100 and 200 nm particles, because of the diffraction 
limit an underestimation of the amount of particles is possible when aggregates are counted as one. 
However, the effect of chromatin targeting is compared to its control situation, in which the same error 
is expected to occur.  
HeLa cells (Human epithelial cervical cancer cells,
Microinjection of HeLa cells 
 ATCC number: CCL-2) were cultured in 
Dulbecco's modified Eagle’s medium: nutrient mixture F-12 (DMEM-F12) (Gibco®) containing 2 mM 
glutamine, 10 % heat inactivated fetal bovine serum (Hyclone/Perbio®) and 100 U/ml penicillin-
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streptomycin liquid (Gibco®) at 37 °C in a humidified atmosphere containing 5 % CO2. For 
microinjection experiments, HeLa cells (2.5x104 cells/cm2) were plated onto sterile glass bottom culture 
dishes (MatTek Corporation®) and allowed to adhere for 1 day. Microinjection with the polystyrene 
beads (green or red) or Cy5-pDNA/PEI nanoparticles (red) was performed with a Femtojet® 
microinjector and an Injectman® NI 2 micromanipulator (Eppendorf®) mounted on a Nikon EZC1-si 
confocal laser scanning microscope. Injections were performed in the cytoplasm, using polystyrene 
beads or pDNA/PEI complexes in HEPES buffer. Injection solutions were supplemented with 2 mg/ml 
70 kDa TRITC-dextran (Sigma-Aldrich®) to identify the place of injection and cell division. After 
microinjection, cells were put back into the incubator and fluorescence microscopy images were taken 
30 minutes and 24 hours after injection. Labelling of the lysosomes was performed by adding 1 µl 
LysosensorTM
 
 green (Invitrogen®) to the microinjected cells. Labelling of the endosomes was 
performed by transfecting the cells with CellLight™ Early Endosomes-GFP BacMam 2.0 
(Invitrogen®). Colocalisation of injected fluorescent red beads with the labelled cell compartments was 
analyzed using Image J (http://rsbweb.nih.gov/ij/). 
RESULTS.  
As non-targeted nanoparticles, we made use of polystyrene beads of 100, 200 and 500 nm as this is 
the size range in which most of the non-viral gene delivery complexes are situated. Initially, also 
polystyrene beads of 20 and 40 nm were included in the study, as model particles that should be able to 
cross the NPCs. However, due to problems of functionalization, aggregation and detection of these 
weakly fluorescent particles, these smaller particles were omitted from the further study. 
Characteristics of non-targeted and targeted nanoparticles 
First, the carboxylated polystyrene beads, as bought from the manufacturer, were functionalized to 
obtain positively charged or PEG-ylated beads. In table 1, the mean diameter (nm) and ζ-potential (mV) 
of these different kinds of nanoparticles are presented. It can be seen that for a given size, the negatively 
charged beads are always slighty larger than stated by the manufacturer. Also, making the beads 
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positively charged or PEG-ylated results in a further size increase. The ζ-potential demonstrates that we 
indeed succeeded in making positively charged particles. In the case of PEG-ylated particles, the ζ-
potential becomes less negative due to the presence of the PEG-chains.   
 
Table 1. Mean diameter (nm) and ζ-potential (mV) of the positively charged (pos), poly-
ethyleneglycol (PEG)-ylated (PEG) and negatively charged (neg) polystyrene beads and of pDNA/PEI 
(poly-ethylene-imine) complexes made with non-modified PEI and PEI modified with Mel-28, mutated 
Mel-28 and HMGA2β. The given standard deviations are the result of repeated measurements.  
 
500 nm beads 200 nm beads 100 nm beads pDNA/PEI complexes 
 
neg PEG pos neg PEG pos neg PEG pos 
non-
targeted Mel28 mut HMGA2β 
Size 
(nm) 577 ± 4 608 ± 10 589 ± 3 233 ± 1 249 ± 2 248 ± 2 116 ± 1 134 ± 1 122 ± 2 168 ± 10 131 ± 6 154 ± 7 238 ± 6 
ζ (mV) -52 ± 1 -29 ± 1 26 ± 1 -47 ± 1 -30 ± 1 26 ± 1 -45 ± 2 -23 ± 1 29 ± 1 29 ± 3 21 ± 2 22 ± 2 17 ± 2 
 
Apart from polystyrene beads, also pDNA/PEI nanoparticles were used as a model for non-viral gene 
delivery vehicles. PEI was chosen as complexation partner for the pDNA to form pDNA/PEI polyplexes 
as it is a well-characterized polymer for gene delivery which is hypothesized to be able to enter the 
nucleus during transfection33. To obtain chromatin targeted nanoparticles, both the 100 nm beads and 
the pDNA/PEI polyplexes were modified with chromatin binding peptides. As chromatin targeting 
peptides, part of the proteins Mel-28, mutated Mel-28 or HMGA2β were chosen. These peptides contain 
an AT-hook, a DNA binding motif found in a family of proteins that binds the minor groove of the AT-
rich scaffold-associated regions (SARs) on metaphase chromosomes34. Mel-28 is associated with two 
types of structures in the cell, one implicated in nuclear-envelope function and the other in chromatin 
organization, and is recruited to chromatin at an early time point during nuclear assembly35, 36. 
HMGA2β is a small non-histone chromatin-associated protein that belongs to the family of the HMG 
proteins, architectural factors which regulate the chromatin structure by specifically binding and 
bending the DNA and creating active and inactive chromatin regions which are essential for gene 
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expression37-39. Figure 2A shows the sequences of the AT-hooks which were used. The specific 
targeting of Mel-28 (GST-AT) and HMGA2β (GST-ATHMGA2β) to the chromatin can be seen after 
immunostaining of the GST-fragment of the chromatin targeting peptides (Figure 2B), while GST alone, 
or GST-tagged mutated Mel-28 (GST-ATMUT
 
) does not stain the chromatin. Table 1 also contains the 
mean diameter (nm) and ζ-potential (mV) of the pDNA/PEI polyplexes before and after 
functionalization with the chromatin targeting peptides. It can be seen that the charge of the 
functionalized polyplexes slightly decreases, while the size slightly decreases for Mel28 and mutated 
Mel28, but increases for HMGA2β. Due to the small sample volume and cost of material, the diameter 
and ζ-potential of the targeted beads could not be measured.   
 
Figure 2. Sequence (A) and in vitro chromatin-targeting properties (B) of Mel-28 (GST-AT), GST 
alone, mutated Mel-28 (GST-ATMUT) and HMGA2β (GST-ATHMGA2β
 
). Only Mel-28 and HMGA2β 
target to the chromatin (stained blue with DAPI, upper panel), as can be concluded from the green 
immunostaining against GST (lower panel).    
The artificial nuclei (Fig. 3) are obtained with the Xenopus nuclear envelope reassembly (XNER) 
assay. In this assay, sperm chromatin is first mixed with cytosolic extract which results in a partial 
decondensation of the sperm chromatin. It should be noted that Xenopus sperm chromatin is much more 
compact than normal mitotic chromatin but is spontaneously repackaged with histones in the cytosolic 
Nuclear inclusion of non-targeted polystyrene beads with different size/charge in the XNER assay 
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extract to become normal mitotic chromatin40-44. Then, upon the addition of membrane extract and an 
ATP generating buffer, the membrane fractions bind to the chromatin and eventually fuse so that 
nuclear membranes are formed around the chromatin material. Then, the chromatin decondenses further 
and nuclear proteins are imported resulting in the swelling of the nuclei so that functional artificial 
nuclei are formed40, 41, 43-46
Figure 3 shows representative examples of artificial nuclei obtained with the XNER assay. Depending 
on where in the sample the pictures are taken, more or less membrane elements or beads seem to be 
present, although the total number of particles and membrane elements in each situation is comparable. 
Also, only fully decondensed nuclei (> 25 µm) were counted as the smaller ones represent unfinished 
nuclei and should not be taken into account. Between 50 and 100 of these large, functional nuclei were 
analyzed for each experiment with a different type of nanoparticles. The results are summarized in 
figure 4 showing the percentage of nuclei containing 0, between 1 and 5, between 6 and 10, or more 
than 10 nanoparticles. It can be seen, in figure 3 as well as in figure 4, that from time to time the non-
targeted beads are enclosed in the artificial nuclei but enclosure is rather limited. Nevertheless, size and 
charge do have an influence on nuclear entry (Fig. 4). The enclosure of the positively charged beads is 
higher than the enclosure of the negatively charged or the PEG-ylated ones. Apart from the charge, it 
can be seen that also size matters, beads with a diameter of 200 nm and 100 nm were better enclosed 
than the 500 nm ones. Thus, the diameter, volume and/or weight can impair the inclusion. We conclude 
that small (100 - 200 nm) positively charged beads have the best chance to be retained in the nucleus 
upon cell division.   
. By addition of fluorescently labelled nanoparticles to the XNER assay, we 
could evaluate the efficiency with which different types of nanoparticles are entrapped in the formed 
nuclei.  
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Figure 3. Representative confocal fluorescence images of the limited nuclear enclosure of non-targeted 
beads (100 nm, positively charged [A]; 200 nm, positively charged [B]; 500 nm, positively charged  
[C]) and chromatin-targeted beads (100 nm, HMGA2β [D]) in artificial Xenopus nuclei. Blue: sperm 
chromatin; orange: membrane fraction; green: polystyrene beads. Only fully decondensed nuclei (> 25 
µm) were counted.   
 
 
Figure 4. Enclosure of non-targeted polystyrene beads of different size (500, 200 or 100 nm) and ζ-
potential (positive, PEG-ylated or negative) in artificial Xenopus nuclei. The percentage of nuclei (as 
denoted in the y-axis) containing 0, 1-5, 6-10 and >10 beads is shown. Only fully decondensed nuclei (> 
25 µm) were counted. The error bars come out of at least 3 independent experiments where 50 to 100 
nuclei were counted per experiment. Half of the corresponding er ror  bars are presented for preventing 
overlap, respectively in the directions minus, minus, minus and plus. 
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In these experiments, not only the inclusion in the artificial nuclei, but also the initial binding to 
chromatin before adding the membrane fraction to the XNER assay was determined. Figure 5A shows 
that the enclosure of beads modified with the chromatin binding peptides derived from Mel-28 or 
HMGA2β is indeed higher than the enclosure of the best non-targeted beads (100 nm, positively 
charged) and the beads modified with the mutated AT-hook (Mel-28 mut), showing the potential of 
chromatin targeting. To verify if chromatin targeting also had an influence on pDNA complexes used in 
non-viral gene delivery, red labelled pDNA/PEI polyplexes were added to the XNER assay and their 
chromatin binding and nuclear inclusion was visualised (Fig. 5B). Also here, the use of chromatin-
targeting AT-hooks Mel-28 and HMGA2β resulted in a 2 to 3 fold increase in nanoparticles which were 
included in the artificial nuclei. Thus, targeting to the chromatin can indeed enhance the nuclear 
inclusion, although it should be noted that not all particles initially bound to the chromatin get included 
in the artificial nuclei (Fig. 5A, B and C).  Assuming that one chromatin strand leads to the formation of 
one artificial nucleus, HMGA2β-targeted particles are the most resistant to displacement, since 
respectively about 45 %, 75 %, 45 % and 30 % of the initially chromatin-bound particles are included in 
the eventually formed artificial nuclei in the case of non-targeted, HMGA2β, Mel-28 and mutated Mel-
28 modified nanoparticles.  
Nuclear inclusion of chromatin-targeted polystyrene beads and pDNA/PEI complexes in the XNER 
assay 
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Figure 5. Average number of particles per chromatin strand (purple bars) and average number of 
particles per artificial nucleus (blue bars) with non-targeted (positively charged) and targeted 100 nm 
polystyrene beads (A) or 7.5 kDa linear pDNA/PEI complexes (B). Between 25 and 50 chromatin 
strands and artificial nuclei were counted. A 2-3 fold targeting when compared to non-targeted beads or 
polyplexes can be observed. The microscopy images (C) show a representative picture of pDNA/PEI 
complexes (red) bound to the chromatin (blue) or included in the XNER nuclei. 
 
We were interested to see whether polystyrene beads (100 nm) and pDNA/PEI complexes which are 
present in the cytoplasm, gain access to the nucleus during cell division. Since figure 5A and B show 
that even for non-targeted positively charged nanoparticles about 45 % of the particles that bind to 
chromatin are retained in the formed nuclei, we would expect to find at least some chromatin binding 
particles in the nuclei of the daughter cells. To circumvent endocytosis and the need for endosomal 
escape, the non-targeted nanoparticles were delivered by directly injecting them into the cytoplasm of 
HeLa cells. Injection solutions were supplemented with TRITC-dextran to identify the place of injection 
and whether or not injected cells divide. Figure 6 shows representative images of the intracellular 
distribution of 100 nm positively charged polystyrene beads (green) and pDNA/PEI polyplexes (red) 
during cell division, in injected living HeLa cells. Initially, the polystyrene beads spread through the 
cytoplasm, while the pDNA/PEI complexes remained closer to the place of injection (indicated by an 
arrow). Also, the pDNA/PEI complexes can be seen to ‘line up’ at the nuclear membrane, demonstrating 
that they are not ‘pushed’ through the NPCs by the applied injection pressure. Upon cell division, it can 
be seen that both the polystyrene beads and the pDNA/PEI complexes are evenly distributed over the 
two daughter cells, but accumulate in the perinuclear region of the daughter cells, rather than being 
present in the nuclei of these cells. Indeed, enclosure of nanoparticles in the nuclei of cells which had 
undergone division was never observed. This is in contrast to the nuclear inclusion seen in assembled 
Nuclear inclusion of microinjected polystyrene beads and pDNA/PEI polyplexes in HeLa cells 
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nuclei in the XNER assay, where there were about 10 pDNA/PEI complexes present in the case of non-
targeted complexes (see Fig. 5B). Apart from non-targeted nanoparticles, also nanoparticles targeted 
with HMGA2β were used for microinjection (Fig. 6C). HMGA2β was chosen as the data in figure 5 
pointed out that in this case, the largest fraction of chromatin-bound nanoparticles is retained in the 
formed nuclei. Also here, however, the nanoparticles were never observed in the nuclei of divided cells, 
but again accumulated in this specific perinuclear region. Whether the nanoparticles first reach the 
nuclear interior and are then expelled to this perinuclear region, or accumulate in this perinuclear region 
already before cell division occurs is not clear.   
 
 
Figure 6. Intracellular distribution upon microinjection of nanoparticles in HeLa cells. A) Polystyrene 
beads (100 nm, positively charged, green), B) pDNA/PEI polyplexes (about 170 nm, positively charged, 
red), C) pDNA/PEI-HMGA2β polyplexes (about 240 nm, positively charged, red) and 70 kDa TRITC-
dextran (orange) as a co-injection marker. Pictures of the injected cells were taken 30 minutes and 24 
hours after injection. An arrow indicates the initial place of injection.  
 
Identification of the specific perinuclear region where nanoparticles tend to accumulate 
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Since we found that the injected polystyrene beads or pDNA/PEI complexes both accumulate in a 
specific perinuclear region, we were interested to determine what this perinuclear region could be. 
Therefore, we performed staining of cell compartments such as the early endosomes and the lysosomes. 
To prevent overlap between the staining colour  and the injected beads, red fluorescent beads were 
injected instead of green ones. Colocalization of the red and the green channel was determined in Image 
J after a background subtract, so that colocalized pixels appear white, while non-colocalized pixels 
appear green or red in the overlay image. Figure 7A shows that there is no colocalization between the 
injected beads and the early endosomes: no white pixels are found in the colocalization image. When 
the lysosomes were stained, however, a great amount of colocalization was observed after 24 hours of 
incubation (Fig. 7C). This is an interesting observation which implies that nanoparticles can end up in 
the lysosomal compartment even when they are directly injected in the cytoplasm and not taken up by 
endocytosis. When the colocalization with the lysosomes was evaluated immediately after injection, no 
colocalization was found (Fig. 7B), indicating that the colocalization observed after 24 hours is not an 
ar tefact, but indeed results from the accumulation of the injected nanoparticles in the lysosomal 
compartment. It should be noted that when performing microinjections, there is a constant flow of 
nanoparticles from the injection needle. Therefore, one could argue that the nanoparticles in the 
surrounding environment can be taken up by endocytosis and end up in the lysosomes in this way. It can 
be seen, however, that mainly the injected cells contain the nanoparticles, showing that the endocytosis 
of free nanoparticles in the medium is negligible.    
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Figure 7. Identification of the perinuclear region upon microinjection of red polystyrene beads in HeLa 
cells. 70 kDa TRITC-dextran was used as a co-injection marker. Pictures of the injected cells were taken 
30 minutes (B) or 24 hours (A,C) after injection. The green panel shows the labelling of the endosomes 
(A) or the lysosomes (B and C). The TRITC panel shows the injected (divided) cells, while the Cy5 
panel shows the injected red beads. Colocalization of the red beads with the green endosomes or 
lysosomes was evaluated using image J. Colocalized pixels appear white in the colocalization image.   
 
DISCUSSION. What happens with nanoparticles during cell division, is a highly relevant question in 
gene delivery, both with regard to biological activity and toxicity issues47. Most studies focusing on the 
intracellular fate of molecules during cell division are however performed with macromolecules such as 
free pDNA or dextrans or with smaller gold particles (30-170 Å)25. The nuclear inclusion of larger 
nanoparticles, such as those used in this study, has not previously been systematically studied in either 
cell-free systems or living cells. In living cell experiments, this can partially be explained by the 
difficulties to inject particles which are larger than 200 nm because of problems of aggregation, needle 
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clogging and long-term survival of the cells after injection. Using the cell-free XNER assay (which is 
the only way to isolate the process of nuclear inclusion), however, we were able to investigate the 
influence of size and charge of nanoparticles on their nuclear inclusion and found that 100 or 200 nm 
particles were more efficiently included than those of 500 nm. We hypothesize that smaller particles are 
due to their smaller size more efficient in penetrating the more narrow regions in the condensed 
chromatin. Therefore, they have access to a larger surface of the chromatin and can be anchored more 
easily e.g. when they are surrounded by chromatin in those grooves. For a given size, positively charged 
nanoparticles were most efficiently included in the nuclei, followed by the negatively charged or PEG-
ylated ones, which can most likely be explained by aspecific interactions of the positively charged beads 
with the negatively charged chromatin. It should be noted that for both the positively and negatively 
charged beads, interactions of the beads with poly-ions or proteins of the cytosolic extract, before 
nuclear reassembly starts, could influence the overall charge and nuclear inclusion of the beads. This 
could explain why the negatively charged beads are better included then the PEG-ylated ones, since the 
inert PEG-chains lack the possibility to interact with the cytosolic poly-ions, proteins or chromatin 
material during the reassembly reaction, although the PEG-ylated beads also possessed a slightly 
negative charge (see table 1). Furthermore, we were able to demonstrate that nanoparticles or 
pDNA/PEI complexes which are targeted to the chromatin have about 2-3 times higher probability of 
being retained in the artificial nuclei. However, not all the particles which were first bound to the 
chromatin, were finally included in the nuclei. Most likely, adding the membrane fraction, which is the 
next step in the XNER assay, results in competition for binding to the chromatin, causing the majority 
of chromatin-bound nanoparticles (purple bars in Fig. 5) to dissociate from the chromatin when the 
nuclear membrane formation proceeds. Figure 5 shows that a higher  number  of pDNA/PEI 
complexes is enclosed in the ar tificial nuclei when compared to polystyrene beads. This can be the 
result of multiple factors. We believe this can be related to the heterogeneity of the pDNA/PEI 
complexes, which can influence the charge distr ibution on their  sur face, the size and the shape of 
the complexes. The resulting larger  sur face or  charge density is expected to give r ise to more 
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effective binding and therefore inclusion of the complexes to a larger  extent. Additionally, it is not 
unlikely that the presence of DNA itself accounts for  a great deal for  the differences observed 
between the pDNA/PEI complexes and the polystyrene beads. Par tially exposed DNA in the 
pDNA/PEI complexes could for example be anchored to the chromatin through the interaction 
with DNA binding proteins.  
Based on these observations in the XNER assay, we conclude that it should be possible to bring 
nanoparticles into the nuclei of dividing cells, providing that they are not too large and are able to bind 
to the chromatin either by their intrinsic positive charge or through the use of chromatin binding 
peptides. However, unlike with the XNER assay, nuclear inclusion in dividing HeLa cells was never 
observed. Instead, the nanoparticles accumulated in a perinuclear region, which corresponds to the 
lysosomal compartment as evidenced by colocalization experiments. Two hypotheses could explain the 
lack of nuclear inclusion and the specific perinuclear distribution observed in living cells: 1) the 
nanoparticles are trafficked to the perinuclear region even before cell division occurs and are therefore 
not free but separated from the chromatin during cell division or 2) the nanoparticles are included in the 
nuclei during cell division but are expelled from the nuclei and subsequently accumulate in the 
perinuclear region. To examine these hypotheses, extensive, detailed real-time analysis of the 
intracellular distribution of the microinjected nanoparticles would be needed. The first hypothesis is 
favoured by the observation that the nanoparticles are present in the perinuclear region where typically 
also lysosomes and endosomal vesicles accumulate. This would imply that after microinjection, the 
foreign nanoparticles are recognized by the endosomal machinery and are entrapped in lysosomal 
vesicles which traffic to the perinuclear region and physically separate the nanoparticles from the 
chromatin during cell division. Nativo and colleagues also detected that a large population of one of 
their modified gold nanoparticles group in the vicinity of the nucleus. They stated these were associated 
to damaged or aberrant endosomes48. In relation to recent studies which indicate that nanoparticles are 
potent autophagy activators, the vesicles we observe can be part of cytoplasmic secretion, exocytosis or 
autophagy, a process by which the cell recycles and subsequently degrades its own components and 
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clears itself of nanoparticles49. Chithrani and colleagues showed that nanoparticles about to be removed 
from cells appeared to be localized in late endosomes and lysosomes27. Also, this could explain the 
differences between the observations in the XNER assay and living cells, since in cell-free systems, 
mitotic spindles are totally absent and the influence of endocytosis/autophagy cannot be studied. This 
shows that we should not assume results obtained from cell-free studies will all apply to living cells, in 
which additional barriers have to be taken into account 41, 50
The second hypothesis would imply that the nanoparticles can bind the chromatin, but that there is a 
mechanism which is able to remove the nanoparticles again so that they are not included in the 
maturated nuclei. Or the chromatin binding is not strong enough to hold the ‘big’ nanoparticles or there 
must be a yet unknown ‘eliminating’ mechanism. Ludtke et al. and Swanson et al. showed that after 
cytoplasmic delivery by microinjection or scratch-loading, the bulk of labelled pDNA or dextran (> 40 
kDa) remained cytoplasmic regardless of cell division. After nuclear injection, however, the labelled 
pDNA or dextran (> 40 kDa) was nuclear in undivided cells, but mainly cytoplasmic in divided cells
. We do believe, however, that the XNER 
assay is a valuable platform for testing ‘new’ chromatin or nuclear targeting vehicles, because it isolates 
the nuclear envelope reassembly without the influence of other barriers such as cellular uptake or 
endosomal escape.  
51, 
52, supporting the idea that only the chromosomes themselves and macromolecules physically associated 
with them were included in the newly formed nuclei52, 53. They did not mention the possibility that the 
macromolecules can be inside immature nuclei and can be excluded later. In contrast, Gasiorowski and 
Dean have shown that naked, unmodified pDNA microinjected directly into the nucleus was able to 
partition evenly to the two daughter nuclei, but that this postmitotic nuclear retention was altered by 
DNA labelling methods, resulting in nuclear exclusion of labelled pDNA, while non-modified pDNA 
was retained54.  In this study, we cannot exclude that the labelling of our pDNA has an influence on the 
nuclear exclusion of our pDNA/PEI polyplexes. It should be noted, however, that in our study the 
labelled pDNA is mainly present in the core of the pDNA/PEI polyplexes and is therefore not expected 
to significantly alter the intracellular behavior of these particles. Also in the case of the labelled 
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polystyrene beads the fluorophores are present inside the core of the nanoparticles and is not expected to 
influence the intracellular distribution of these beads.  
In summary, although nuclear inclusion was observed in the XNER assay, we hypothesize that in 
living cells the nanoparticles are either intracellularly ‘trapped’ in vesicles and are thus not free to bind 
to the chromatin, or do indeed enter the nuclei of dividing cells, but are again expelled and then 
accumulate in the lysosomal compartment. The nature of the mechanism that prevents the nuclear 
inclusion of nanoparticles in living HeLa cells, is a topic that requires further study. It is, however, an 
interesting observation that nanoparticles which were injected in the cytoplasm of cells end up in the 
lysosomal compartment, even when they are not taken up by endocytosis. This implies the possibility to 
“endocytose” nanoparticles which are free in the cytosol, a mechanism which requires further 
investigation as this is highly relevant towards all sorts of gene delivery vehicles. We do believe, 
however, that nuclear inclusion should be possible when the nanoparticles are free in the cytoplasm at 
the onset of cell division. Also, as the XNER assay demonstrated, anchoring the nanoparticles to the 
chromatin by chromatin targeting peptides could help to improve the nuclear inclusion. This makes it an 
attractive future strategy for non-viral gene delivery, providing that other intracellular barriers such as 
the entrapment in the lysosomal compartment are first overcome.     
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